о побочных оттуда же:
Rates of adverse events were similar in the placebo and rosuvastatin groups except for a slightly higher rate of muscle symptoms with rosuvastatin (Table 3). Rates of myalgia, muscle weakness, and myopathy were not significantly different among rosuvastatin-allocated patients with and without LDL-C <50 mg/dl. Diabetes mellitus as an adverse event was reported more frequently among rosuvastatin-allocated patients attaining LDL-C <50 mg/dl than among rosuvastatin-allocated patients who did not attain LDL-C <50 mg/dl, but this difference was not significant (1.6 vs. 1.2 per 100 person-years, p = 0.70). Rates of psychiatric adverse events, fatigue, peripheral neuropathy, cancer, hematuria, proteinuria, and renal failure did not differ between the rosuvastatin and placebo groups. Reports of hematuria were more frequent (p = 0.03) in rosuvastatin-allocated patients with LDL-C <50 mg/dl when compared with placebo, whereas depression (p = 0.005) and colon cancer (p = 0.04) were reported less frequently.
|